Wolverine World Wide, BioMarin Pharmaceutical, Datadog, Progressive and Klaviyo are part of the Zacks Screen of the Week article.…
…
…
…
San Francisco (www.aktiencheck.de) - Rating-Update:
Die Einschätzung von Mohit Bansal, Analyst von Wells Fargo Advisors, für die Aktie von BioMarin Pharmaceutical…
…
…
BioMarin (BMRN) delivered earnings and revenue surprises of 18.33% and 0.14%, respectively, for the quarter ended March 2024. Do the…
This year, the biotech industry anticipates a resurgence with increased M&A, FDA approvals, and AI-driven innovations. Given the industry’s rosy…
…
…
…
Pro Research: Wall Street examines BioMarin Pharmaceuticals prospects…
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron…
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…
…
Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…
…
…
…
Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical are included in this Analyst Blog.…
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-08-08...…
Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2023-08-07...…
Davis, George Eric - Vorstand - Tag der Transaktion: 2023-08-08...…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioMarin (BMRN) beats on earnings and sales estimates in the second quarter on the back of robust demand for Voxzogo....…
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended…
BioMarin (BMRN) delivered earnings and revenue surprises of 14.89% and 0.65%, respectively, for the quarter ended June 2023. Do the…
WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) announced earnings for its second quarter that increased from the same period last…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
VOXZOGO® Growth Continued in the Second Quarter Driven by Global Demand Resulting in Increased Full Year 2023 Guidance Pivotal Program…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
read more...…
SAN RAFAEL, Calif., July 12, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Following FDAs approval, BioMarins (BMRN) Roctavian becomes the first gene therapy for treating severe hemophilia A....…
WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced the FDA approved ROCTAVIAN gene therapy for the treatment of adults with…
BioMarin Pharmaceutical Inc. BMRN received Food and Drug Administration approval of its gene therapy Roctavian to treat hemophilia A, the…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
The potential FDA approval of BioMarins gene therapy for hemophilia A would be a major win, but patient uptake could…
Um den gesamten Artikel unter globenewswire.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioMarin (BMRN) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…
SAN RAFAEL, Calif., May 4, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues....…
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter…
BioMarin (BMRN) delivered earnings and revenue surprises of 39.53% and 4.17%, respectively, for the quarter ended March 2023. Do the…
WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) revealed a profit for first quarter that decreased from the same period last…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…